GPC1 and familial pancreatic carcinoma: Although no EV-based biomarkers are currently used for diagnostic or prognostic purposes, there are multiple studies assessing the clinical use of EVs in cancer, including a clinical trial of Gylpican-1+ (GPC1+) EVs for the diagnosis of pancreatic cancer [53].